Amantadine monotherapy of chronic hepatitis C patients infected with genotype lb

H Senturk; A Mert; M Akdogan; F Tabak; G Basaran; S Turkoglu; G Ozbay; S Badur

doi:10.1080/003655400458965

Amantadine monotherapy of chronic hepatitis C patients infected with genotype lb

Scand J Infect Dis. 2000;32(5):575-6. doi: 10.1080/003655400458965.

Authors

H Senturk¹, A Mert, M Akdogan, F Tabak, G Basaran, S Turkoglu, G Ozbay, S Badur

Affiliation

¹ Department of Internal Medicine, Cerrahpasa Medical Faculty of Istanbul University, Turkey.

PMID: 11055673
DOI: 10.1080/003655400458965

Abstract

We aimed to test the efficacy of amantadine in chronic hepatitis C (CHC) patients infected with genotype b. Twenty patients completed treatment with amantadine HCl, 100 mg b.i.d., for 6 months. Non-sustained biochemical improvement was observed without loss of HCV-RNA. We conclude that amantadine monotherapy is not effective in CHC.

MeSH terms

Adolescent
Adult
Amantadine / therapeutic use*
Antiviral Agents / therapeutic use*
Female
Genotype
Hepacivirus / classification*
Hepacivirus / genetics
Hepatitis C, Chronic / drug therapy*
Hepatitis C, Chronic / virology
Humans
Male
Middle Aged
RNA, Viral / blood
Treatment Failure

Substances

Antiviral Agents
RNA, Viral
Amantadine